Partnership with Milner Research Institute
Repure Life Science has signed Partnership with the Milner Therapeutics Institute
Repure Life Science has partnered with the Milner Therapeutics Institute in the UK.
The Milner Therapeutics Institute is part of the University of Cambridge and is part of the Cambridge Biomedical Campus. The main task is to accelerate academic research towards medical development through close collaborative interaction with industry.
The Milner Therapeutics Institute will provide a 'Match-Making' service through the Milner Therapeutics Consortium.
Utilizing the pharmaceutical industry's pharmaceutical development expertise and resources, it connects world-class research potentials at Cambridge University and its partner institutions.
In June, Repure Life Science and Milner Therapeutics Institute signed an MOU. (Current Tony Kouzarides, director of the Milner Therapeutics Institute, Cambridge University)
This will allow Repure Life Science to meet with more than 400 representatives from academia and industry at annual events and to interact with academic and pharmaceutical companies and affiliate partners of the Milner Therapeutics Consortium and to communicate with scholars from all over the world, as well as from Korea and the UK.
It is expected that Repure Life Sciences will interact with the world's leading pharmaceutical industry through the Milner Therapeutics Institute, based on the accumulated knowledge and research environment of the University of Cambridge, has a long history of more than 800 years, founded in 1209.